Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients

This study (PHANTASTIC) compares first-line plerixafor with granulocyte colony-stimulating factor (G-CSF) in 98 myeloma and lymphoma patients with 151 historic controls mobilised by conventional chemotherapy+G-CSF. Eleven patients developed mild transient symptoms possibly related to plerixafor. No...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, R E, Bell, J, Clark, J O, Braithwaite, B, Vithanarachchi, U, McGinnity, N, Callaghan, T, Francis, S, Salim, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220652/
https://www.ncbi.nlm.nih.gov/pubmed/25360901
http://dx.doi.org/10.1038/bcj.2014.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220652/
https://www.ncbi.nlm.nih.gov/pubmed/25360901
http://dx.doi.org/10.1038/bcj.2014.79

Ejemplares similares